Highlight Therapeutics

iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia.

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. Gate2Brain pursues its goals using a radically innovative peptide-based patented technology platform. G2B-002, Gate2Brain flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare paediatric cancers.

Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues and cells. We are focusing the application of our technology in fields like Mechanobiology where the study of diseases directly related with cell migration or development are demanding new techniques. We offer cutting-edge non-invasive to...

Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs target the secretory translocon (Sec61 channel) in cells to selectively block and degrade harmful extracellular proteins before they can be secreted and cause disease.

Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with NeoMag, the first magneto-mechanical platform designed to simulate real pathological processes on biological systems. By combining smart materials with AI-driven models, we induce precise, non-invasive mechanical forces directly onto cells. NeoMag bridges the gap between the lab bench and living tissue, accelerating drug discovery and significantly reducing the need for animal testing. Our US/EU patented tech, tested in word class labs like Institut Pasteur or Imperial College, uses AI and smart materials to apply precise 2D/3D forces. Backed by prestigious programas like EIC Transition, and an award-winning scientific team, we provide ultra-predictive models that accelerate drug discovery to Pharmas and Biotechs in fields like cancer, derma or neuro.

Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The company's medical devices are useful in measuring the level of biomarkers in body fluids such as saliva, tears, sweat, sputum, feces, urine or blood, enabling medical professionals to detect and treat various infectious diseases.

Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus is on developing non-invasive blood-based solutions for the early detection of cancer, during a time when treatment options are more abundant and survival rates are higher. UDX strongly believes that detecting cancer at an early stage is the most effective way to combat it. Their diagnostic platform is designed to identify various types of cancer, such as colorectal, prostate, liver, pancreatic, lung, and breast cancer (which accounts for over 50% of all new cancer cases per year), through a single blood test. This is made possible by using a curated collection of proprietary methylation markers. The blood sample can be taken during a routine check-up and then processed at a reference laboratory or hospital using standard equipment. The results are then uploaded to the UDX Cloud for final analysis using an algorithm. UDX's initial marker panel focuses on screening for colorectal cancer, which helps identify individuals who should be referred for colonoscopy. Colorectal cancer is the third most common cancer and the second most deadly cancer worldwide. However, it is often detected at later stages, resulting in significantly lower survival rates (11% in stage IV compared to 85% in stage I). To support the development of their test and carry out necessary research and operations, UDX collaborates with international research institutions, hospitals, universities, and biobanks across the globe.

Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded by scientists from the Plant Biotechnology research group in 2009. The company leverages the expertise gained by this group over three decades to develop products and solutions for the commercial market. Specializing in Plant Biotechnology, Phyture Biotech produces valuable active ingredients and recombinant proteins for the cosmetics and pharmaceutical industries. In 2016, the company rebranded as Vytrus Biotech.

Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly biodegradable ones. Through the application of a quality management system and in compliance with the necessary regulatory framework, they deal with all stages of product development, from fundamental research through market introduction.

Overture Life is a biotechnology company that specializes in developing automated technologies for assisted reproductive procedures, with the goal of improving the efficiency and availability of in vitro fertilization (IVF). Their solutions focus on automating intricate processes in the embryology lab, such as egg freezing and embryo thawing, in order to enhance consistency and lower expenses. The company's DaVitri platform is designed to standardize these procedures, potentially leading to higher oocyte survival rates and reducing the necessity for multiple IVF cycles.

In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun off from the University of Valencia in Spain, conducts research and develops innovative oligonucleotide treatments that control microRNA. In order to produce exploratory miR-modulating oligonucleotides that are intended to enter pertinent tissues in pharmacological quantities and treat disorders in which microRNAs play a significant role, ARTHEx has created its own technology, the ENTRY TM platform. ATX-01, an antimiR for Myotonic Dystrophy Type 1 that is in preclinical development, is the first experimental medicine from this technology (DM1) More than 900,000 people worldwide suffer from DM1, an orphan disease for which there is currently neither a cure nor an approved treatment.